Advanced Center for Treatment Research and Education in Cancer, Tata Memorial Center, Mumbai, Homi Bhabha National Institute, India.
International Institute for Population Sciences, Mumbai, India.
Asian Pac J Cancer Prev. 2023 Apr 1;24(4):1199-1207. doi: 10.31557/APJCP.2023.24.4.1199.
The purpose of this study was to report quality of life of newly diagnosed breast cancer patients from India in a large cohort using the EQ-5D-5L instrument.
The study used longitudinal data of 500 breast cancer and 200 non-cancer subjects registered at our centre, during June 2019 and March 2022. The EQ-5D-5L and EQ-VAS instruments were used to measure and compare utility scores among cancer and non-cancer subjects. Descriptive statistics were analyzed and Tobit regression model were used to confirm the predictors of the utility score.
The cancer subjects had a mean EQ-ED-5L utility score of 0.8703 (SD=0.121), 0.8745 (SD=0.094) and 0.8902 (SD=0.107) at the time of baseline, completion and follow up surveys respectively. EQ-5D-5L values had significantly worsened after diagnosis of cancer as compared to the non-cancer cohort (0.87 vs. 0.93, p value 0.000). EQ-5D-5L utility scores as per stage for the cancer cohort were 0.88, 0.86 and 0.83 respectively for stage I-II, III and IV. Similarly, the EQ-VAS scores for stage I-II, III and IV were 74.9, 72.6 and 73.2 respectively. Multivariate analysis confirmed strong association of age, religion and income with the utility-values.
This is the first longitudinal study reporting the utility scores derived from a large cohort of breast cancer patients demonstrating lower utility scores compared to non-cancer cohort. The utility scores also improve post treatment completion for cancer patients and decrease with higher stage at diagnosis. This information will be useful for future health economic research in India pertaining to breast cancer.
本研究旨在使用 EQ-5D-5L 工具报告印度新诊断乳腺癌患者的生活质量。
该研究使用了 2019 年 6 月至 2022 年 3 月期间在我们中心注册的 500 名乳腺癌和 200 名非癌症患者的纵向数据。使用 EQ-5D-5L 和 EQ-VAS 工具来衡量和比较癌症和非癌症患者的效用得分。进行了描述性统计分析,并使用 Tobit 回归模型来确认效用得分的预测因素。
癌症患者在基线、完成和随访调查时的 EQ-ED-5L 效用评分平均值分别为 0.8703(SD=0.121)、0.8745(SD=0.094)和 0.8902(SD=0.107)。与非癌症队列相比,癌症诊断后 EQ-5D-5L 值明显恶化(0.87 对 0.93,p 值<0.000)。癌症队列的 EQ-5D-5L 效用评分按分期分别为 I-II 期、III 期和 IV 期的 0.88、0.86 和 0.83。同样,I-II 期、III 期和 IV 期的 EQ-VAS 评分分别为 74.9、72.6 和 73.2。多变量分析证实,年龄、宗教和收入与效用值密切相关。
这是第一项报告来自大型乳腺癌患者队列的效用评分的纵向研究,与非癌症队列相比,该队列的效用评分较低。癌症患者在治疗完成后效用评分有所提高,而在诊断时分期越高,效用评分则越低。这些信息将对未来印度乳腺癌相关健康经济学研究有用。